Latest news with #Dexcom
Business Wire
8 hours ago
- Business
- Business Wire
Tenovi Expands Access to Glucose Data for Remote Patient Monitoring and Cardiometabolic Programs Through Dexcom Integration
PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Tenovi, a leading provider of remote patient monitoring (RPM) solutions, today announced it now supports Dexcom continuous glucose monitoring (CGM) data directly within its clinician-facing dashboard. This milestone expands Tenovi's ability to support diabetes management programs across healthcare organizations by seamlessly displaying Dexcom CGM data within its existing virtual RPM infrastructure. Through this integration, Tenovi now supports hourly average glucose data visualization for patients using Dexcom real-time CGMs. Healthcare teams using Tenovi's platform can view glucose trends alongside other vital health RPM metrics, without the need to distribute or manage physical inventory of CGM devices. 'Access to glucose insights is vital to managing chronic conditions such as diabetes,' said Iftah Mashav, Chief Growth Officer at Tenovi. 'A Dexcom and Tenovi integration allows our clients to leverage CGM data in virtual care models that are flexible, scalable, and rooted in clinical outcomes.' This expansion supports Tenovi's broader suite of telemetry solutions designed for cardiometabolic populations, an area of growing focus for health plans and employer-sponsored programs. By enabling continuous remote access to essential health data, Tenovi helps organizations improve outcomes, reduce costs, and scale value-based care. Tenovi provides secure data access via the Dexcom API, allowing health systems to onboard patients seamlessly without the burden of physical device logistics. Dexcom data access is now live on the Tenovi platform. Healthcare organizations can begin enrolling eligible patients immediately. To learn more or schedule a demo, visit About Tenovi Tenovi is a data aggregation and automation Healthcare IoT platform that connects medical device manufacturers with remote patient monitoring programs. It provides over 40 remote patient monitoring and remote therapeutic monitoring (RTM) device point solutions that integrate with its proprietary Cellular Gateway, automating the transfer of patient vitals. Tenovi's API-driven fulfillment and automation services enable seamless deployment of remote patient and therapeutic monitoring programs. For more information, visit
Business Insider
2 days ago
- Business
- Business Insider
Wells Fargo Remains a Buy on Dexcom (DXCM)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom yesterday and set a price target of $98.00. The company's shares closed yesterday at $84.03. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Biegelsen is a 4-star analyst with an average return of 6.1% and a 55.00% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Dexcom, Medtronic, and Abbott Laboratories. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $99.46 average price target, a 18.36% upside from current levels. In a report released on July 16, Mizuho Securities also upgraded the stock to a Buy with a $100.00 price target. The company has a one-year high of $113.28 and a one-year low of $57.52. Currently, Dexcom has an average volume of 3.6M.
CNET
5 days ago
- Health
- CNET
These Continuous Glucose Monitors Have Been Recalled Due to Faulty Speakers. What You Need to Do to Stay Safe
Dexcom customers, listen up: certain continuous glucose monitoring receivers have been recalled due to speaker malfunctions, which can cause you to miss alerts or alarms for dangerous blood sugar levels. Since May 2025, there have been 112 complaints globally, with 56 reported injuries. Missing an alert from your continuous glucose monitor may result in health consequences like vomiting, seizures, loss of consciousness and hypoglycemic or hyperglycemic symptoms. Certain Dexcom G6, G7, One and One Plus receivers are included in this recall. The One and One+ receivers are available outside of the US. Dexcom is one of the most popular continuous glucose monitor brands, and many people with diabetes use Dexcom devices to track their glucose levels in real time. According to Dexcom's update, even without the audio output from the speaker, your receiver will still alert you through vibration and visual prompts. However, that's only so helpful when many people keep their receivers in their pockets or bags. People who use the mobile app for glucose values, alerts and alarms will still be able to do so without interruption. What you should do right now A continuous glucose monitoring system has three parts: the glucose sensor you wear, a transmitter and the small receiver you keep for alerts. The receiver is being recalled, not the sensor you wear, so you shouldn't expect the readings you get from your device to be inaccurate. If you use a Dexcom continuous glucose monitor, check the complete list of affected devices for the model and serial number. You can also go to Dexcom's website to see if your device is affected. These numbers are on the back of your receiver. If your device is affected, contact Dexcom immediately for a free replacement. Continuous glucose monitors aren't something you can just stop using, so it's essential to get in your replacement order as soon as possible. Remember, while you wait, that there's a chance your receiver speaker isn't working correctly and you will not be alerted with a sound to spikes or drops in your blood sugar. You should regularly test the speakers each time you charge your receiver. When you plug the receiver in, the Speaker Test screen will appear for a few seconds. To test your sound, follow the directions on the screen. If it doesn't beep, then it's time to contact Dexcom. Remember that it's important to continue testing your speaker over time. Checking it once doesn't mean it can't fail in the future. Even if your device isn't under recall, this is a good habit to have. You can also test your receiver's speaker at any time through the device's menu. For support during this recall, contact Dexcom technical support at 1-844-478-1600.
RTÉ News
6 days ago
- Business
- RTÉ News
Abbott beats profit estimates on medical devices demand
Abbott has today beaten Wall Street estimates for second-quarter profit, driven by strong demand for its medical devices including continuous glucose monitors. But its third-quarter earnings forecast fell short of expectations. Abbott expects profit of between $1.28 and $1.32 per share, below expectation of $1.34. Sales of its continuous glucose monitoring devices, which include the FreeStyle Libre series and Lingo, jumped 21.4% to $1.9 billion in the second quarter. Continuous glucose monitor makers such as Abbott, Dexcom and Medtronic are riding a surge in demand as diabetes awareness rises, insurance coverage expands, and patients embrace finger-prick-free technology. Abbott's quarterly revenue came in at $11.14 billion, beating expectations of $11.07 billion, according to data compiled by LSEG. The medical device business, which sells diabetes and heart-related devices among others, posted sales of $5.37 billion, topping estimates of $5.24 billion. On an adjusted basis, the company reported a profit of $1.26 per share for the second quarter, compared with analysts' average estimate of $1.25. Abbott said today it planned to build a manufacturing facility in the US state of Georgia by 2028 to support its cardiovascular business. This adds to April announcements for manufacturing and research projects in Illinois and Texas, which are expected to go live by the end of the year, and help Abbott mitigate any likely impact from President Donald Trump's tariffs.
Yahoo
6 days ago
- Business
- Yahoo
Abbott beats quarterly profit estimates on medical devices demand
(Reuters) -Abbott beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors. Continuous glucose monitor makers such as Abbott, Dexcom and Medtronic are riding a surge in demand as diabetes awareness rises, insurance coverage expands, and patients embrace finger-prick-free technology. On an adjusted basis, the company reported a profit of $1.26 per share for the second quarter, compared with analysts' average estimate of $1.25, according to data compiled by LSEG. Abbott's quarterly revenue came in at $11.1 billion, in line with expectations. The medical device business, which sells diabetes and heart-related devices among others, posted sales of $5.37 billion, topping estimates of $5.24 billion. Abbott said on Thursday it planned to build a manufacturing facility in the U.S state of Georgia by 2028 to support its cardiovascular business. This adds to April announcements for manufacturing and research projects in Illinois and Texas, which are expected to go live by the end of the year, and help Abbott mitigate any likely impact from President Donald Trump's tariffs. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
